In this report we describe our experience with two patients in order to evaluate the clinical potential of a reduced intensity stem cell transplantation in a more difficult clinical setting, i.e. second transplant with a one- or two-antigen mismatched related donor for relapsed and refractory leukemia. Three benefits were hoped for: 1) reduced regimen-related toxicity, 2) potent engraftment facilitation, and 3) an intense anti-leukemia effect.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Aug 7 2001|
All Science Journal Classification (ASJC) codes